Eton Pharmaceuticals, Inc. Additional Paid in Capital, Common Stock
Eton Pharmaceuticals, Inc. (ETON) had Additional Paid in Capital, Common Stock of $145.92 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-13
- 2026-06-30: Additional Paid in Capital, Common Stock $145.92M.
- 2026-03-31: Additional Paid in Capital, Common Stock $141.53M.
- 2025-12-31: Additional Paid in Capital, Common Stock $138.62M.
- 2025-03-31: Additional Paid in Capital, Common Stock $133.89M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $145.92M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $141.53M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $138.62M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $133.89M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $132.29M 10-K · filed 2026-03-19 |
| 2024-09-30 | $123.25M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $121.36M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $120.35M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $119.52M 10-K · filed 2025-03-18 |
| 2023-09-30 | $118.68M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $117.93M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $117.01M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $116.19M 10-K · filed 2024-03-14 |
| 2022-09-30 | $115.20M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $114.22M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $112.80M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $111.72M 10-K · filed 2023-03-16 |
| 2021-09-30 | $110.79M 10-Q · filed 2021-11-16 |
| 2021-06-30 | $109.77M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $108.57M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $107.80M 10-K · filed 2022-03-16 |
| 2020-09-30 | $85.84M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $84.98M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $83.84M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $74.72M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |